The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7
years) of early initiation of everolimus and early elimination of CsA compared to standard
immunosuppressive regimen including CsA on primary and secondary endpoints investigated in
the SCHEDULE (NCT01266148) main study.